Navigation Links
Operating without interrupting warfarin reduces risk of bleeding after cardiac device surgery
Date:5/10/2013

DENVER, May 9, 2013 A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care. The new findings were released today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, and will be published online today in The New England Journal of Medicine (NEJM).

At least a quarter of patients that require pacemaker or implantable defibrillator surgery are taking warfarin to reduce the risk of a stroke. Current guidelines recommend bridging many of these patients to heparin treatment and stopping anticoagulation therapy in the days leading up to surgery which can put a patient at risk of a stroke. The Bruise Control trial is the largest randomized clinical trial to compare continuing warfarin to temporary cessation with heparin bridging in patients before and after device surgery.

"We hope that Bruise Control will change how we are treating patients around the world," said lead author David Birnie, MD, Director of the Arrhythmia Service at the University of Ottawa Heart Institute, Canada. "Our study conclusively shows that treating patients with a high risk of stroke with continued warfarin instead of heparin bridging will improve patient outcomes, decrease complications and reduce hospitalization."

Bruise Control randomized 681 patients at 17 Canadian and 1 Brazilian center with a less than 5 percent annual risk of thrombo-embolic events. One group received continued warfarin, while the other patients were bridged to therapeutic doses of either intravenous heparin or subcutaneous low-molecular-weight heparin starting three days before the procedure and resuming 24 hours after surgery. Patients were evaluated after surgery and the study found that clinically significant hematomas were 80 percent less frequent in patients t
'/>"/>

Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-761-4427
University of Ottawa Heart Institute
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Danai Brooks Joins Dyadic International as Chief Operating Officer
2. Regeneron Reports First Quarter 2013 Financial and Operating Results
3. AFcell Medical Hires Chief Operating Officer
4. - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -
5. Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
6. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Millions of DNA switches that power human genomes operating system are discovered
9. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
10. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The November 2014 issue of BioTechniques ( ... journal featuring the following articles:, , ... in the retina , DNA from fingermarks ... chromogenic substrates in zebrafish , Re-use of ... , Nuclear LC3-positive puncta in stressed cells ...
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:11/21/2014)... 20, 2014 /CNW/ - Aequus Pharmaceuticals Inc. (the ... it has closed a brokered private placement offering ... C$3.7 million.  Cormark Securities Inc. and Clarus Securities ... Offering for a syndicate of agents that also ... (collectively the "Agents"). Concurrently with the Brokered Offering, ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... International,Corporation (Nasdaq: PRXL ) will release Second Quarter ... after the close of the,stock market. The announcement will ... on the PR Newswire website at, http://www.prnewswire.com ., ... at 10:00 a.m. ET,on Thursday, January 24, 2008 to ...
... update on QuatRx clinical development programs, including review of positive ... ... ANN ARBOR, Mich., Jan. 4 QuatRx Pharmaceuticals Company,today announced ... a presenter at the 26th Annual JP Morgan Healthcare,Conference on Tuesday, ...
... BOSTON, Jan. 4 Follica Inc., a privately ... (male and female pattern hair,loss caused by androgens ... follicle disorders, today announced a $5.5 million Series ... existing,investors PureTech Ventures participated. The funding is expected ...
Cached Biology Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call 2QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 2Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic 3
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... study published in this month,s Proceedings of ... of a recently discovered communication molecule of the body,s ... known to limit inflammation and the current study reports ... the ability of the immune system to recognize and ... IL-37,s effect on the immune system now allows us ...
(Date:11/3/2014)... Researchers from Australia report that low birth weight and ... (OA)-related hip replacements in adulthood. Findings published in the ... & Research , indicate that low birth weight and ... arthroplasty due to OA as adults. , According ... of 25 are diagnosed with clinical OA. Symptoms of ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... 23, 2010) A clue to the causes of ... tiny intercellular junction that rapidly transfers information from one ... University School of Medicine, with students from the Sackler ... called APC (adenomatous polyposis coli) plays a key role ...
... viral genes protected monkeys infected with deadly Ebola or ... therapeutics were administered one hour after exposuresuggesting the approach ... hospital settings. The research, which appears in today,s ... was conducted by the U.S. Army Medical Research Institute ...
... the University of Minnesota Academic Health Center have identified two ... for HIV. The two drugs, decitabine and gemcitabine ... therapy were found to eliminate HIV infection in the ... death an outcome researchers dubbed "lethal mutagenesis." This ...
Cached Biology News:Researchers connect APC protein to autism and mental retardation 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 2Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses 3U of M researchers identify 2 FDA approved drugs that may fight HIV 2
... that will help protect your PCR runs ... work area prior to use, reducing the ... Containment features reduce the chance of airborne ... for a clear view, an acid-resistant black ...
...
... glass slide in this set of ... in triplicate, for a total of ... proteins as internal control. Antibodies belonging ... angiogenesis, apoptosis, cell cycle progression, signal ...
...
Biology Products: